SCHEMBL2516637

SCHEMBL2516637

O=C(Oc1ccccc1)C(c1ccccc1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.59
ATM Q13315 2/20 0.59
TDP1 Q9NUW8 2/20 0.54
CHRM1 P11229 5/20 0.49
CHRM3 P20309 5/20 0.49
CHRM2 P08172 4/20 0.49
CHRM4 P08173 4/20 0.49
KLK7 P49862 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
LMNA P02545 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27871613 0.98 L3MBTL1 (0.58) L3MBTL1ATMTDP1CHRM1CHRM3
SCHEMBL8652438 0.98 L3MBTL1 (0.58) L3MBTL1ATMTDP1CHRM1CHRM3
SCHEMBL1550630 0.98 L3MBTL1 (0.58) L3MBTL1ATMTDP1CHRM1CHRM3
SCHEMBL10911370 0.98 L3MBTL1 (0.58) L3MBTL1ATMTDP1CHRM1CHRM3
SCHEMBL28722007 0.98 L3MBTL1 (0.58) L3MBTL1ATMTDP1CHRM1CHRM3
SCHEMBL1395561 0.88 L3MBTL1 (0.49) L3MBTL1ATMTDP1CHRM1CHRM3
SCHEMBL27635695 0.88 PTGS1 (0.55) L3MBTL1ATMTDP1CHRM1CHRM3
SCHEMBL1489979 0.87 L3MBTL1 (0.51) L3MBTL1ATMTDP1CHRM1CHRM3
SCHEMBL11603067 0.83 L3MBTL1 (0.59) L3MBTL1ATMTDP1LMNACYP1A2
P-Cresol SCHEMBL1867060 0.81 L3MBTL1 (0.54) L3MBTL1ATMCHRM1CHRM3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025243208-A2 PROCESS FOR THE PREPARATION AND/OR PURIFICATION OF POLYETHYLENE GLYCOL AND ITS DERIVATIVES, OBTAINED PRODUCT AND USES THEREOF HOVIONE - FARMACIÊNCIA, SA (PT) 2025-11-27 WO claimed
WO-2024046339-A1 PHARMACEUTICAL FORMULATION COMPRISING COMBINATION OF LONG-ACTING INHALED STEROID AND LONG-ACTING β2 RECEPTOR AGONIST 立生医药(苏州)有限公司 2024-03-07 WO claimed
US-20240018147-A1 SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE HAISCO PHARMACEUTICALS PTE. LTD. (CN) 2024-01-18 US claimed
EP-4212534-A1 SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE Haisco Pharmaceuticals Pte. Ltd. (SG) 2023-07-19 EP claimed
CN-115073391-B Novel crystal form of pramipexole triphenacetate and preparation method thereof 山东京卫制药有限公司 2023-04-07 CN claimed
CN-218653369-U Filtering and concentrating device for crude product of triphenylacetic acid 安徽有吉医药科技有限公司 2023-03-21 CN claimed
CN-115215818-B Pramipexole triphenyl acetate and drug sustained release preparation thereof 山东京卫制药有限公司 2023-03-17 CN claimed
CN-115802893-A Fungicidal compositions 先正达农作物保护股份公司 2023-03-14 CN claimed
CN-115745945-A Method for preparing vilanterol intermediate by one-pot method 奥锐特药业股份有限公司 2023-03-07 CN claimed
CN-115721625-A Pharmaceutical composition containing mirabegron and preparation and application thereof 山东威智中科药业有限公司 2023-03-03 CN claimed
CN-112876507-A Trisubstituted olefin tertiary phosphine compound and preparation method thereof 湖北大学 2021-06-01 CN claimed
CN-112262852-A Triphenylacetic acid tin dispersible oil suspending agent and preparation method thereof 浙江禾本科技股份有限公司 2021-01-26 CN claimed
CN-111807973-A Preparation method of vilanterol and salt thereof 上海谷森医药有限公司 2020-10-23 CN claimed
CN-110740644-A Fungicidal compositions 先正达参股股份有限公司 2020-01-31 CN claimed
US-20150239862-A1 PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF PERRIGO API LTD. (IL) 2015-08-27 US claimed
WO-2014041565-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF LAURUS LABS PRIVATE LIMITED (IN) 2014-03-20 WO claimed
EP-1431984-A1 Polymer resistor composition having a substantially neutral temperature coefficient of resistance and methods and compositions relating thereto E. I. du Pont de Nemours and Company (US) 2004-06-23 EP claimed
US-20040113127-A1 Resistor compositions having a substantially neutral temperature coefficient of resistance and methods and compositions relating thereto E.I. DU PONT DE NEMOURS AND COMPANY 2004-06-17 US claimed
US-5663030-A A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT XEROX CORPORATION (US) 1997-09-02 US claimed
US-4332962-A RHODIUM COMPOUND AS CATALYST FOR CYCLIZATION OF A PENTADIENE IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1982-06-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239862-A1 PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF VAT1, VKORC1L1, VKORC1 L3MBTL1 4322/4885ATM 4711/4885TDP1 3521/4885
US-20240018147-A1 SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE BTK, SYK, LYN L3MBTL1 3286/4885ATM 197/4885TDP1 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.